Breast lesions detected by MRI and classified as BI-RADS 2 were shown to not be malignant, and therefore do not need biopsy.
Breast biopsies are unnecessary for breast lesions found by breast MRI and characterized as BI-RADS 2, according to a study published in the journal Clinical Radiology.
Researchers from Austria performed a retrospective single-center study to assess the frequency of malignancies in lesions characterized as benign on breast MRI.
A total of 1,265 patients, mean age 50, were included in the study. All had undergone dynamic contrast-enhanced MRI (1.5 T) of the breast during a six-year period.
The researchers examined the MRI characteristics and frequency of malignancy in 192 of the patients found to have breast lesions classified as BI-RADS 2.
The lesions were either histopathologically verified or subjected to both clinical and imaging follow-up of at least two years (range: two to nine years).
The results showed that no lesions that were classified as BI-RADS 2 were found to be malignant. “Histopathology was available in 67 (34.9%) lesions and revealed benign findings exclusively,” the authors wrote. “The remaining 125 (65.1%) lesions did not exhibit changes during the follow-up period and were, therefore, considered negative for malignancy.”
The researchers concluded that breast biopsies are unnecessary for breast lesions classified as BI-RADS 2, due to the absence of malignancies.
MRI-Based Deep Learning Algorithm Shows Comparable Detection of csPCa to Radiologists
May 8th 2024In a study involving over 1,000 visible prostate lesions on biparametric MRI, a deep learning algorithm detected 96 percent of clinically significant prostate cancer (csPCa) in comparison to a 98 percent detection rate for an expert genitourinary radiologist.
Breast MRI and Dense Breasts: A Closer Look at Early Findings from a New Prospective Trial
May 2nd 2024Supplemental breast MRI had a cancer detection rate (CDR) of 20/1000 and a positive predictive value (PPV) of 50 percent, according to preliminary findings from a prospective trial involving women with heterogeneously or very dense breasts.